How to get Abstracts From Liver Meeting 2008 (AASLD)

[jmjm530]

Here's how to access the abstracts at Liver Meeting 2008.  A list of all abstracts under the heading of "viral hepatitis" will follow.  Not sure if late breaking abstracts are included.

(1) Go to: http://www.aasld.org/Pages/Default.aspx
(2) Register (We're all Hep C researchers, aren't we)
(3) Sign in
(4) click on "Liver meeting 2008"
(5) click on "Abstract and Presenters" (left bar)
(6) click on "View Itinerary Planner"
(7) click on "Search" (left bar)
(8) Fill out Search forum as appropriate. For the global search below, I simply went to "categories" and chose "viral hepatitis" from the drop down menu. I left the other fields blank. For more specific searches -- such as by sub topics or author - fill out appropriate fields.

[jmjm530]

I guess the computer is not smart enough to be context sensitive (or I'm not smart enough to realize that) ! Once more, what is missing is "d o t  c o m"

[jmjm530]

******* was starred out, above, but hopefully I'm not violating any rules since the site is medical and not commercial. Like Clinical Care Options and Projects In Knowledge, that site is an excellent resource.

[jmjm530]

Looks like hivandhepatitis ******* has finally started their annual capsulated coverage of AASLD  with easy to access hot links. Hopefully it will be more complete soon.

http://www.hivandhepatitis.com/2008icr/aasld/main.html

[jmjm530]

Thanks for bringing this one to my attention.  I'm going to post the study in its own thread. .

[portann]

Again, thanks.

Based on ID # 1851, I sure wish I were more anemic, less than 10!

[mikesimon]

Thanks a bunch. Mike

[smaug48]

Very helpful, Jim, thanks for taking the time to do this for everyone.  Much appreciated!

smaug

[merryBe]

holy motherload there jmjm.....I guess this explains why my doctor doesn't know all I think he should!!!   Heaven's to Mergatroid ......

no wonder someone said....whose got time to even look at all the posters....
how are providers supposed to keep up with that much stuff being offered in one week!
It's no wonder even doc who go to these don't know the half of it.

mb

[bajawoman]

Found a lot of good reading and have copied several studies to discuss with my doctor
and ditto on the time you spent  Thanks

[susan400]

Wow, Jim, thanks alot!  It will take me several days to pick through all these and decide which I want to read, but thanks so much for taking the time to do this!  

Susan400

[NashPred]

I think I’m thinking of something else with powerpoint slides of data available like a seminar.

Thanks again for the info. A LOT of good stuff to sort through here.

[Rockerforlife]

Awesome links to information..thanx

[jmjm530]

Here's a better link to those Quick Links from the hc advocate web site:
http://tinyurl.com/5eeams

[jmjm530]

I think this is pretty much it except for late breaking presentations which usually end up on the site near the end.

This site here usually has summaries of key articles but they don't appear up yet -- maybe in a few days:

http://www.hivandhepatitis.com/

Also some quick links here from another site:

http://preview.tinyurl.com/5eeams

[NashPred]

Thanks for the info jmjm.

I know the meeting is not even over yet....but does anyone know when, if, or where the full summary of these presentations will be made available?

[Rockerforlife]

I have have of herbal "extracts" but this is even too much for me

[portann]

Thank you, Jim. It was easier for me to plant two hundred spring bulbs today than it will be to wade through our new curriculum.

Quick question about something I noticed, unrelated to the conference study papers themselves but to the current list of substances harmful to the liver, as posted on your link in one of the tabs. It had a rather odd conclusion about the Roche COBAS TaqMan and TaqMan 48 Analyzers, that  the "FDA considers that the probability of life threatening consequences is likely to occur by the malfunctioning of these devices."


"Drug Alerts
AASLD » Your Liver » Drug Alerts » Roche COBAS TaqMan and TaqMan 48 Analyzers
Roche COBAS TaqMan and TaqMan 48 Analyzers  
FDA and Roche Molecular Systems
FDA and Roche Molecular Systems notified healthcare professionals of a Class 1 recall of the Roche COBAS TaqMan and TaqMan 48 Analyzer, used for the measurement of hepatitis B and hepatitis C viruses and for other in-house diagnostic testing. The analyzers produced falsely elevated values due to the improper seating of a fiber optic cable in the analyzer instrument. FDA considers that the probability of life threatening consequences is likely to occur by the malfunctioning of these devices.



-----------------------------------------------------------------------------------------------------------

Is this old news and now insignificant due to the necessary correction?

And now to the more serious matter at hand, picking a study to read.....any hot ones recommended by those more diligent than I've been? Shall I just cut to the highlights or do my own slogging through the brush? See you in a week....:)

    

[jmjm530]

Thanks for the heads up about not needing to register to gain access to the abstracts.

For some reason I thought you needed to, but then again the path to those abstracts is not exactly intuitive so maybe I didn't find it the first time without registering.

As to the doc's -- just because there name is on a paper doesn't mean they will physically be there to present. I'm sure there's a list of presenters somewhere.

For anyone interested in just a couple of the abstracts, you can probably just plug the abstract number into the search page athough I don't have it in front of me now.

-- Jim

[jmjm530]

Sorry Rocker, it's nothing you can eat or put in a shake.

[Rockerforlife]

What in the hell is all this?

[jmjm530]

May have missed some in the copy and paste but that's what I got.

[jmjm530]

Tue, Nov 04
8:00 AM
No itinerary selected

1933. Effects of Hepatitis C Virus Core Protein on Insulin Signaling: Study of Core Protein of different Genotypes and Amino-acid Sequence Analysis .  C. Sophie; S. Pascarella; V. Pazienza; K. Guilloux; S. Conzelmann; F. Negro View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1960. Difference of Liver Stiffness after Acute or Chronic Liver Injury due to Viral Hepatitis.  J. Kim; H. . Yim; Y. Jung; J. Kim; Y. Seo; J. Yeon; S. Um; K. Byun View Pres.



1938. Effect of Rituximab on advanced liver disease in patients with HCV-related mixed cryoglobulinemia.  A. Petrarca; L. Rigacci; U. Arena; F. Vizzutti; C. Giannini; P. Montalto; A. Bosi; S. Colagrande; P. Romagnoli; G. Laffi; A. Zignego View Pres.


1932. Selective up-regulation of interferon-inducible genes and type 1 and type 2 interferons in the brain of patients with hepatitis C and severe depression .  M. Trippler; K. Truebner; T. Bajanowski; S. Bein; G. Gerken; J. F. Schlaak View Pres.



1951. Diabetes Mellitus is Associated with more Advanced Stage of Liver Fibrosis in Patients with Chronic Hepatitis C Infection. .  M. Sanon; E. Bou Assaf; S. Kirtich; G. Bahtiyar; S. I. McFarlane; A. Aytaman View Pres.


1947. HCV infection and carotid atherosclerosis: evidence in favor of a local viral action inside the plaque..  M. Boddi; B. Chellini; R. Marcucci; F. Sofi; C. Giannini; L. Gragnani; A. Piluso; D. Prisco; R. Abbate; A. Zignego View Pres.



1958. Transient Elastography (TE) as a tool to evaluate acute liver damage: a prospective, multicentric cohort study .  V. Di Marco; A. Iacò; F. Bronte; V. Calvaruso; M. Puoti; L. Biasi; K. Prestini; R. Bruno; D. Achilli; G. Squadrito; G. Amaddeo; A. Craxì View Pres.



1942. A PROSPECTIVE ANALYSIS OF FIBROTEST-FIBROSURE (FT) PROGNOSTIC VALUE AT 10 YEARS IN PATIENTS WITH CHRONIC HEPATITIS C (CHC).  Y. Ngo; M. Munteanu ; D. Messous; F. Charlotte; F. Imbert-Bismut; D. Thabut; P. Lebray; V. Thibault; Y. Benhamou; V. Ratziu; T. Poynard View Pres.


1934. Hiperbilirubinemia in patients with chronic hepatitis C may be due to UGT1A1 promoter polymorphisms. .  M. M. Souza; S. K. Ono-Nita; C. S. Ferreira; C. Zanini; H. S. Paschoale; P. D. Nasser; E. P. Carmo; M. E. Nita; F. J. Carrilho View Pres.

[jmjm530]

1945. Association of Lipid Profiles with Hepatitis C Viral Load in Chronic Hepatitis C Patients with Genotype 1 and 2 Infection.  C. Hsu; C. Liu; C. Liu; M. Lai; P. Chen; D. Chen; J. Kao View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1946. Low Rate of Anamnestic Response to Hepatitis B Vaccine in Patients with HIV and Isolated Hepatitis B Virus (HBV) Core Antibody.  I. G. Harnik; P. Heeger; D. A. Fishbein View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1957. Hepatitis A viremia in the course of hepatitis A by real-time PCR.  K. Fujiwara; H. Kojima; S. Yasui; Y. Yonemitsu; M. Arai; K. Fukai; F. Imazeki; O. Yokosuka View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1931. Prospective evaluation by paired liver biopsy of HCV disease progression in patients (pts) co-infected with HIV. .  R. K. Sterling; P. G. Smith; J. Wegelin; M. L. Shiffman; R. T. Stravitz; V. A. Luketic; M. Fuchs; A. J. Sanyal View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1937. Increasing CD4 Percentage During Chronic HCV Treatment In An HIV/HCV Integrated Clinical Cohort .  L. Beauchamps; J. S. Kalpoe; D. Tider; A. Stivala; D. A. Fishbein View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1935. Prevalence and Predictors of Liver Fibrosis in Hepatitis C (HCV) Infected Hemophilic Men .  M. Ragni; K. Soadwa; M. A. Nalesnik; Q. Dang View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1939. Effect of Anti-TNF-α Blockers on serum ALT levels in Potential Hepatitis B Virus Occult Carriers.  J. Sohn; T. Kim; Y. Jeon; D. Han; C. Eun; H. Choi View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1940. IP-10 correlates with HCV viral load, hepatic inflammation and fibrosis and predicts HCV response, relapse or non-response in HIV-HCV co-infection.  T. Reiberger; J. H. Aberle; M. Kundi; A. Rieger; H. Holzmann; M. Peck-Radosavljevic View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1941. Marginal zone lymphoma and HCV infection: role of antiviral treatment.  A. M. Pellicelli; G. Barbaro; V. Zoli; D. Remotti; R. Villani; L. Nosotti; A. Picardi; U. Vespasiani Gentilucci; F. Soccorsi View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1952. Hepatocellular Carcinoma associated to chronic Hepatitis Delta.  R. Romeo; A. Russo; A. Sangiovanni; E. Del Ninno; M. Rumi; M. Colombo View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1949. Insulin Resistance is Not Associated with Histologic Severity in Nondiabetic, Noncirrhotic Patients with Chronic Hepatitis B Virus Infection.  S. Park; D. Kim; Y. Kim; B. Kim View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1943. The presence of additional diagnoses in patients with chronic hepatitis B and C. Histological evaluation of liver biopsies used for correlation with Transient Elastography in 257 patients..  C. Verveer; P. E. Zondervan; H. L. Janssen; R. J. de Knegt View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1950. Epidemiology and genetic analysis of Hepatocellular Carcinoma in Morocco.  S. Benjelloun; A. Essaid El Feydi; A. Marchio; A. Akil; L. ElKihal; R. Afifi; M. Hassar; M. Benazzouz; S. Ezzikouri; P. Pineau View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1930. Whole Genome Transcriptional Profiling in Peripheral Blood Mononuclear Cells Illustrates Unique Pathogenic Characteristics of HCV Mixed Cryoglobulinemic Vasculitis .  S. Kottilil; A. C. Frank; J. Yang; R. A. Lempicki; M. G. Ghany; M. Sneller View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1936. A clinicopathological comparison of HIV/Hepatitis B co-infection and Hepatitis B mono-infection in Cape Town, South Africa.  M. W. Sonderup; H. Wainwright; H. N. Hairwadzi; C. W. Spearman View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1955. Clinical Impact of Hepatitis E Virus (HEV) on Acute Hepatitis of Unknown Etiology During 10 Years in Sapporo, Japan.  J. Kang; H. Mizuo; Y. Karino; T. Matsui; J. Koyama; S. Honjo; T. Arakawa; H. Okamoto; S. Mishiro View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1959. 11-year Change of Hepatitis A Prevalence in Single City of Korea.  J. Lee; D. Son; H. Park; H. Park; J. Park; J. Lee; S. Jung; D. Lee; H. Kim; Y. Shin; Y. Kim View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1953. HBEAG-POSITIVE DELTA HEPATITIS: VIROLOGICAL; BIOCHEMICAL AND CLINICAL FEATURES IN A LARGE EUROPEAN MULTICENTER DATA BASE .  B. Heidrich; H. Wedemeyer; M. Bektas; R. Idilman; F. Önder; A. Bozdayi; K. Zachou; K. Deterding; R. Raupach; H. Bozkaya; M. P. Manns; C. Yurdaydin View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1944. Predictors of liver related mortality and morbidity in chronic HBsAg carriers.  Y. Ngo; V. Thibault; M. Rachel; D. Rousselot-Bonnefont; V. Ratziu; T. Poynard; Y. Benhamou View Pres.


Tue, Nov 04
8:00 AM
No itinerary selected

1948. What should be the definition of normal ALT serum level for identification of chronic hepatitis B inactive carrier? .  Y. Ngo; V. Thibault; M. Rachel; V. Ratziu; D. Rousselot-Bonnefont; T. Poynard; Y. Benhamou View Pres.

[jmjm530]

208. Does Induction Pegylated Interferon Alfa-2b in Combination with Ribavirin Enhance The Sustained Response Rates in Patients with Genotype 1 and 4 Chronic Hepatitis C? Results from a Prospective, Randomized, Multi-Center, Open-Label Treatment Study..  D. E. Brady; J. W. An; E. J. Lawitz; S. Harrison View Pres.


262. Strong Racial Differences in Lipid Metabolism Genetic Associations with Hepatic Fibrosis in Chronic Hepatitis C Infected Patients.  J. McCarthy; K. Patel; J. G. McHutchison View Pres.


265. Changes in Health-Related Quality of Life are Associated with Disease Progression and Peginterferon Therapy in Patients with Advanced Hepatitis C in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial.  K. K. Snow; H. L. Bonkovsky; R. J. Fontana; J. H. Hoofnagle; H. Kim View Pres.

266. Naturally occurring STAT-C resistance mutations in treatment-naïve HCV infected patients - an international multi-center study.  T. Kuntzen; J. Timm; A. Berical; A. M. Berlin; C. Oniangue-Ndza; B. Lee; D. Heckerman; J. Carlson; H. R. Rosen; F. K. Bihl; A. Cerny; U. Spengler; Z. Liu; Y. Xing; M. A. Madey; J. F. Fleckenstein; V. M. Park; C. A. Riely; G. Lake-Bakaar; E. S. Daar; I. M. Jacobson; E. D. Gomperts; B. R. Edlin; S. M. Donfield; R. T. Chung; A. Talal; T. N. Marion; B. W. Birren; M. R. Henn; T. M. Allen View Pres.


Tue, Nov 04
12:15 PM
No itinerary selected

267. Decline in Sexual Desire, Function and Satisfaction in Men During Peginterferon and Ribavirin Therapy for Chronic Hepatitis C.  L. M. Dove; R. C. Rosen; D. Ramcharran; A. S. Wahed; S. H. Belle; R. S. Brown; J. H. Hoofnagle View Pres.


Tue, Nov 04
12:30 PM
No itinerary selected

264. Lower Risk of Hepatocellular Carcinoma and Improved Survival in patients with HCV Related Cirrhosis with Sustained Virological Response.  A. F. Cardoso; R. Moucari; N. Giuily; C. G. Figueiredo-Mendes; N. Boyer; M. Ripault; C. Castelnau; T. Asselah; M. Martinot-Peignoux; S. Maylin; C. Stern; P. Bedossa; P. Marcellin View Pres.


Tue, Nov 04
11:45 AM
No itinerary selected

263. Sustained Virological Response is Associated with Decrease in Liver Stiffness Using FibroScan in Patients with HCV Related Cirrhosis.  A. F. Cardoso; C. Stern; R. Moucari; N. Giuily; C. G. Figueiredo-Mendes; N. Boyer; M. Ripault; C. Castelnau; T. Asselah; M. Martinot-Peignoux; S. Maylin; P. Bedossa; P. Marcellin View Pres.


Tue, Nov 04
11:30 AM
No itinerary selected

Session Title: Parallel XXXIII: HCV: Therapeutic Trials

Session Type: Parallel Sessions


Moderator: Bhupinderjit S Anand
Moderator: Andrew Muir

Location: General Session Room (Moscone West Convention Center)

Start time: Tue, Nov 04 - 11:15 AM



268. Sustained Virologic Response (SVR) and Predictors of Response in African American (AA) Patients in the IDEAL (Individualized Dosing Efficacy Versus Flat Dosing to Assess OptimaL Pegylated Interferon Therapy) Phase 3b Study.  J. McCone; K. Hu; J. G. McHutchison; M. L. Shiffman; J. W. King; S. K. Herrine; G. Galler; M. Sulkowski; F. Nunes; K. a. Brown; S. C. Gordon; K. D. Mullen; N. Ravendhran; W. M. Cassidy; R. H. Ghalib; W. Deng; S. Noviello; J. K. Albrecht; A. J. Muir View Pres.


Tue, Nov 04
11:15 AM
No itinerary selected

271. Reduction of Insulin Resistance with Effective Clearance of Hepatitis C Infection: Results from the HALT-C Trial.  A. Delgado-Borrego; S. H. Jordan; B. Negre; D. Healey; W. Lin; D. A. Ludwig; A. F. Lok; J. E. Everhart; R. T. Chung View Pres.


Tue, Nov 04
12:00 PM
No itinerary selected

273. Reduced Hepatic Inflammation is Related to HCV RNA Suppression and Correlates With Less Fibrosis Progression and Fewer Cirrhosis Complications in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.  C. Morishima; M. L. Shiffman; K. Lindsay; G. Szabo; J. L. Dienstag; E. C. Wright View Pres.


Tue, Nov 04
12:30 PM
No itinerary selected

270. Es-Citalopram for the prevention of PEG-IFN-α and Ribavirin associated depression in HCV-infected patients without psychiatric risk factors (CIPPAD-study)..  M. Schaefer; R. Sarkar; U. Spengler; T. Schlaepfer; J. Ockenga; A. Friebe; S. Effenberger; L. M. Heinze; P. Buggisch; J. Reimer; R. Link; A. Klein; B. Hintsche; V. Weich; F. Boemmel; S. Zeuzem; T. Berg View Pres.


Tue, Nov 04
11:45 AM
No itinerary selected

269. A Phase 2b Study of Telaprevir with Peginterferon-Alfa-2a and Ribavirin in Hepatitis C Genotype 1 Null and Partial Responders and Relapsers Following a Prior Course of Peginterferon-Alfa-2a/b and Ribavirin Therapy: PROVE3 Interim Results.  J. G. McHutchison; M. L. Shiffman; N. Terrault; M. P. Manns; A. M. Di Bisceglie; I. M. Jacobson; N. H. Afdhal; E. Heathcote; S. Zeuzem; H. W. Reesink; S. George; N. Adda; A. J. Muir View Pres.


Tue, Nov 04
11:30 AM
No itinerary selected

272. Treatment Week 24 Results of Weight-based Taribavirin Versus Weight-Based Ribavirin, Both with Peginterferon alfa-2b, in Naïve Chronic Hepatitis C, Genotype 1 Patients .  E. Lawitz; A. J. Muir; F. Poordad; E. Chun; J. Hammond View Pres.


Tue, Nov 04
12:15 PM
No itinerary selected

Session Title: Presidential Plenary II

Session Type: Plenary Sessions


Moderator: Scott L Friedman
Moderator: Jacquelyn J Maher

Location: General Session Room (Moscone West Convention Center)

Start time: Mon, Nov 03 - 11:00 AM



158. Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Positive Patients With Chronic Hepatitis B (Study 103), Preliminary Analysis .  E. Heathcote; E. J. Gane; R. A. deMan; S. Chan; W. Sievert; S. Mauss; P. Marcellin; J. Sorbel; J. Anderson; E. Mondou; J. Quinn; F. Rousseau View Pres.


Mon, Nov 03
12:05 PM
No itinerary selected

157. Transcriptional activity of hepatits B virus covalently closed circular DNA(HBV cccDNA) is regulated by methylation.  J. Kim; S. Jeong View Pres.


Mon, Nov 03
11:50 AM
No itinerary selected

Session Title: Presidential Plenary III

Session Type: Plenary Sessions


Moderator: Arun J Sanyal
Moderator: T. Jake Liang

Location: General Session Room (Moscone West Convention Center)

Start time: Tue, Nov 04 - 8:00 AM



242. Peginterferon with or without Ribavirin for Chronic Hepatitis C in Children and Adolescents: Final Results of the PEDS-C Trial.  K. B. Schwarz; R. P. Gonzalez-Peralta; K. F. Murray; J. P. Molleston; B. Haber; M. M. Jonas; P. Mohan; W. F. Balistreri; P. Rosenthal; M. R. Narkewicz; L. J. Smith; P. R. Robuck; B. Barton View Pres.


Tue, Nov 04
9:15 AM
No itinerary selected

243. Telaprevir in Combination with Peginterferon-Alfa-2a with or without Ribavirin in the Treatment of Chronic Hepatitis C: Final Results of the PROVE2 Study.  S. Zeuzem; C. Hezode; P. Ferenci; G. M. Dusheiko; K. Alves; L. Bengtsson; S. Gharakhanian; R. Kauffman; J. J. Alam; J. Pawlotsky View Pres.


Tue, Nov 04
9:30 AM
No itinerary selected

Session Title: Viral Hepatitis: Co-morbidities and Non-B/Non-C Hepatitis Viruses

Session Type: Poster Sessions


Location: West Hall (Moscone West Convention Center)

Start time: Tue, Nov 04 - 8:00 AM